3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Tuberous Sclerosis
3
Seizures
2
Lennox Gastaut Syndrome
2
Epilepsies, Myoclonic
2
Prostatic Neoplasms
1
Neoplasms
1
Marijuana Abuse
1
Liver Cirrhosis
1
Glioblastoma
1
Carcinoma, Intraductal, Noninfiltrating
1
Cancer Pain
1
Breast Carcinoma In Situ
1
Behavior
1
Interventions
Magnetic Resonance Spectroscopy
54
enzalutamide
47
apalutamide
37
Specimen Handling
37
Androgen Antagonists
34
Abiraterone Acetate
32
Prednisone
29
darolutamide
28
Radiosurgery
27
Pluvicto
23
Docetaxel
23
abiraterone
22
Radiotherapy
21
Leuprolide
19
Biopsy
16
relugolix
14
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
14
Surveys and Questionnaires
13
gallium 68 PSMA-11
12
Triptorelin Pamoate
12
Gonadotropin-Releasing Hormone
12
Radiation
11
Nivolumab
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
11
cabazitaxel
10
bicalutamide
10
X-Rays
10
Standard of Care
10
Goserelin
9
Carboplatin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Cannabidiol
×
90 days
×
Clear all
NCT07549256
2026-04-24
ProCan
Regionshospital Nordjylland
Phase 2
Not yet recruiting
58 enrolled